Labcorp to offer FDA-cleared Alzheimer's blood test nationwide
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Labcorp to Offer First FDA-Cleared Blood Test to Detect Alzheimer's Disease Pathology in Both Primary and Specialty Care Settings
August 24, 2026 7:03 AM EDTElecsys® pTau-217 is the first and only FDA-cleared single-biomarker blood test to both rule in and rule out amyloid pathology across specialty and primary care settingsMeasures phosphorylated Tau 217 (pTau-217), an indicator of amyloid pathology and a hallmark of Alzheimer's diseaseIntended for individuals 55 and older with signs, symptoms or complaints of cognitive decline
BURLINGTON, N.C., Aug. 24, 2026 /PRNewswire/ --... More
